Clinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Epigenomics. 2013 Aug;5(4):397-415. doi: 10.2217/epi.13.39.
Non-Hodgkin's lymphomas (NHLs) comprise a large and diverse group of neoplasms of lymphocyte origin with heterogeneous molecular features and clinical manifestations. Current therapies are based on standard chemotherapy, immunotherapy, radiation or stem cell transplantation. The discovery of recurrent mutations in epigenetic enzymes, such as chromatin modifiers and DNA methyltransferases, has provided researchers with a rationale to develop novel inhibitors targeting these enzymes. Several clinical and preclinical studies have demonstrated the efficacy of epigenetic drugs in NHL therapy and a few specific inhibitors have already been approved for clinical use. Here, we provide an overview of current NHL classification and a review of the present literature describing epigenetic alterations in NHL, including a summary of different epigenetic drugs, and their use in preclinical and clinical studies.
非霍奇金淋巴瘤（NHL）是一组起源于淋巴细胞的、具有异质性分子特征和临床表现的大型肿瘤。目前的治疗方法基于标准的化疗、免疫疗法、放疗或干细胞移植。表观遗传酶（如染色质修饰酶和 DNA 甲基转移酶）中的反复突变的发现，为研究人员提供了开发针对这些酶的新型抑制剂的理论基础。一些临床和临床前研究已经证明了表观遗传药物在 NHL 治疗中的疗效，并且已经有几种特定的抑制剂被批准用于临床使用。在这里，我们提供了 NHL 分类的概述，并回顾了描述 NHL 中表观遗传改变的现有文献，包括不同的表观遗传药物的总结及其在临床前和临床研究中的应用。
